Skip to main content
. 2024 Feb 19;98(2):174–184. doi: 10.1159/000537847

Table 1.

Study population characteristics for CAH and control youth

CAH (n = 27) Controls (n = 35) Group difference, p
Age, years 12.6±3.4 13.0±2.8 0.62
Biological sex, n
 Female 16 20 0.87
Male 11 15
BMI z-score 1.61±0.86 0.80±0.95 0.001
Ethnicity, n
 Hispanic 11 20 0.28
Non-Hispanic 16 15
Race, n
 White 19 24 0.64
 Black 1 3
 Asian 2 3
 Native American 0 1
Unknown 5 4
CAH Form, n
 Salt-wasting 24
Simple-virilizing 3
CAH medications
 Glucocorticoid dose, mg/m2/day 15.1±2.9
Fludrocortisone dose, mg/day 0.10±0.04
CAH analytes
 17-OHP, ng/dL 2,125 [736, 4,324]
  nmol/L 64.39 [22.3, 131.02]
 Testosterone, ng/dL 2 [0.7, 6.4]
  nmol/L 0.07 [0.02, 0.22]
 Androstenedione, ng/dL 75 [31, 94]
  nmol/L 2.62 [1.08, 3.28]
 Plasma renin activity, ng/mL/h and µg/L/h 3.46 [1.12, 5.41]
 Highest newborn 17-OHP, ng/dL 15,300 [7,600, 25400]
  nmol/L 463.59 [230.28, 769.62]

Mean ± SD; median [IQR].